MAP2K7 and hepatocellular carcinoma: Because sorafenib is designed to block the RAF/MEK/ERK pathway and induce tumor inhibition in HCC, the reactivation of ERK pathway confers an acquired resistance to BRAF and MEK inhibitors 23.